Stock Ratings / Health Care / INAB / forecast

INTS (47) PASG (51) ATYR (44) BCDA (49) ⌘ Pro Terminal →

IN8bio Inc. (INAB) 12-Month Stock Forecast & Price Target Cone

$0.98 -3.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

IN8bio Inc. (INAB) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $9.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INAB)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your INAB Position Size: $10,000

Shares at $0.98: 10204.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.69

$7,041

$-2,959 (-29.6%)

12M Consensus BaseTarget $0.89

$9,082

$-918 (-9.2%)

12M Bull Case BreakoutTarget $2.87

$29,286

+$19,286 (+192.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$3	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INAB)

✓Walkthrough of INAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.33%📐 HORIZONTAL RANGE

2026-10-30O $0.96H $0.98L $0.90C $0.98VOL 47.9K

RES: $1.57SUP: $0.86SMA50: $1.15SMA200: $1.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INAB Butterfly Map → + Track INAB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INAB)

Health Care Rank #729 of 1016 ⚔️ INTS vs INAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INAB vs. INTS, PASG, ATYR, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IN8bio Inc. (INAB) ranks #729 by composite RQD confidence (38/100, grade D-) and #898 by equity capitalization ($9.7M). Within this direct 5-issuer industry benchmark cohort, INAB leads on earnings valuation at N/A trailing P/E, while INAB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PASG currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with INAB at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INAB ACTIVE IN8bio Inc.	D-	38/100	—	—	-35.0%	-3.91%	$9.7M	Benchmark Subject
INTS Intensity Therapeutics Inc.	D	47/100	—	—	-35.0%	-1.18%	$10.9M	/ints-vs-inab →
PASG Passage Bio Inc.	D	51/100	—	—	-35.0%	+5.71%	$11.3M	/pasg-vs-inab →
ATYR aTyr Pharma Inc.	D	44/100	—	—	-35.0%	+4.56%	$13.5M	/atyr-vs-inab →
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-inab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001740279

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IN8bio Inc. (INAB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.4M, operating cash flow of -$12.7M, and free cash flow of -$12.7M (+47.4% YoY). On the balance sheet, INAB closed FY2025 with $32.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$19.4M	-$12.7M	-$12.7M	$32.3M	—
FY2024 (FY)	2024-12-31	$0	-$30.4M	-$24.1M	-$24.1M	$20.9M	—
FY2023 (FY)	2023-12-31	$0	-$30.0M	-$23.3M	-$23.3M	—	—

3. INAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, IN8bio Inc. (NASDAQ: INAB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.98 (-3.91% 1D, market cap $9.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INAB ranks #729 in composite RQD confidence.

How does INAB compare to INTS and PASG in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M) and PASG (Passage Bio Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -35.0%, cap $11.3M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INAB?

Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $0 in revenue, -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INAB trading relative to its 50-day, 200-day, and 52-week technical levels?

INAB last traded at $0.98 (-3.91% on volume of 1,419 shares), positioning the stock -14.78% below its 50-day simple moving average ($1.15) and -32.41% below its 200-day simple moving average ($1.45). Across its 52-week range of $0.87 to $2.73, INAB sits at the 5.9% percentile with a 14-day RSI of 33.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).

INAB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is INAB's 12-month stock price target?

IN8bio Inc. (INAB) carries a 12-month consensus base price target of $0.89 (-9.2% from $0.98), with a bull-case target of $2.87 and a bear-case floor of $0.69.

Is INAB stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates INAB D- (Sell — SELL) with an RQD Confidence score of 38/100.

Direct Sub-Reports: INAB RQD Cockpit INAB 12M Forecast INAB Earnings & Move INAB Dividends & DRIP INAB Insiders & 13F INAB Whale Options INAB Profit Sankey INAB News & Why